Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Cloroquina
Lopinavir/Ritonavir (Kaletra)
4.-
Causa
posible
s
evento
s
advers
os
gastroi
ntestin
ales
Tocilizumab
Interferones
Favipiravir
Estudio Año País Tip Població Intervenci Compara Objetiv Resultado Balanc
o n ón dor o s e
princip riesgo/
al benefi
cio
lee et 2004 Hon eca “Probabl “early” intraveno clearan Median casos
al(9) g e” cases intraveno us normal ce of time for
Kon of SARS us saline viral SARS- hidroc
g coronavi hydrocorti 5mL eight RNA CoV RNA ortiso
ruswith sone 100 hourly as from to
or mg every placebo, blood become na: 9
without eight for a total undetecta placeb
laborator hourly, of 12 ble in o: 7
y days, or plasma
confirma until was 12 resulta
tion “pulse” days do
accordin methylpre (range subrog
g to the dnisolone 11–20 ado
Center was given days)
for as rescue versus 8
Disease ther- apy. days
Control “Pulse” of (range 8– no se
and intraveno 15 days) reporta
Preventi us high- in the efecto
on (CDC) dose hydrocort s
case methylpre isone and advers
definition dnisolone placebo os
(CDC, (500 groups,
2003) mg/day respectiv el
and (2) for three ely tamañ
age 18– consecuti (Mann– o del
65 years. ve days) Whitney; efecto
was given P = no fue
for cases 0.106). cuantif
having icado
persistent
/recurrent
fever plus
radiograp
hic
progres-
sion of
lung
opacities
±
hypoxemi
a as
rescue
therapy